Psychedelics and the science of self-experience

The paper begins by distinguishing two conceptions of the self that are important for research into consciousness. One is the 'narrative self', a temporally extended, cognitive construct tied to personal history, traits and goals; the other is the 'minimal self', the immediate first‑person sense of being an embodied, agentic subject. This multilayered account highlights why self‑experience is difficult to define and why it presents a challenge for neuroscience, which must address both self‑as‑object (attributional processes) and self‑as‑subject (pre‑reflective experience). Carhart‑Harris and colleagues set out to explore how classic serotonergic psychedelics (5‑HT2A agonists such as psilocybin and LSD) can inform a neuroscience of self. The paper synthesises neuroimaging and electrophysiological findings that relate brain network organisation to self‑experience, considers how psychedelics perturb those networks and discusses implications for psychopathology and therapeutic use. The authors argue that psychedelics, which reliably and transiently produce reductions in the normally bounded sense of self (often described as ego‑dissolution), provide a useful experimental window onto the neuronal correlates of both normal and disturbed self‑experience.

The extracted text does not present a discrete Methods section or report a systematic search strategy; instead, the paper functions as a narrative, theoretical review that integrates prior quantitative and experimental work. The authors draw on a range of empirical sources, including a quantitative meta‑analysis of self‑processing studies (pooled data from nearly 1,500 participants), functional MRI and magnetoencephalography (MEG) experiments examining psychedelics, and recent clinical and non‑clinical studies of psychedelic‑occasioned experiences. Evidence types brought together include task‑based fMRI contrasts comparing self‑specific versus non‑self stimuli, resting‑state network analyses (with emphasis on the default mode network, DMN), MEG measures of oscillatory power, and psychometric work such as the development and validation of an eight‑item Ego‑Dissolution Inventory. The paper also summarises small clinical intervention studies (for example an open‑label psilocybin pilot in treatment‑resistant depression) and correlational work linking mystical or ego‑dissolution experiences to measures of well‑being and personality change. Because no formal methods are reported in the extracted text, details on study selection, inclusion criteria or risk‑of‑bias assessment are not available from this extraction.

The review presents several converging empirical findings. A quantitative meta‑analysis of self‑processing tasks implicated cortical midline structures—most notably the perigenual anterior cingulate cortex—in increased activity when participants processed self‑specific stimuli compared with stimuli about others. These self‑related regions anatomically overlap important nodes of the default mode network (DMN), a set of cortical areas linked to introspection and autobiographical memory and that function as connector hubs at rest. The authors discuss theoretical work suggesting that the minimal self may arise from predictive processing mechanisms that minimise mismatch between predicted and incoming sensory signals, conferring a pre‑reflective sense of familiarity, ownership and agency. Empirical studies using classic psychedelics fit this framework: psilocybin and LSD decrease the integrity of resting‑state networks such as the DMN and reduce segregation between networks, producing greater whole‑brain functional integration. These network changes correlate with participants' ratings of ego‑dissolution. An MEG study reported that psilocybin‑induced ego‑dissolution correlates with reduced alpha power in the posterior cingulate cortex, a core DMN hub. Two LSD studies similarly found that ego‑dissolution correlated with increased whole‑brain integration and inversely with DMN integrity, reduced functional connectivity between the parahippocampus and retrosplenial cortex, and decreased delta and alpha oscillatory power. Noting a methodological gap, the authors report that earlier psychedelic experiments lacked independently validated measures of ego‑dissolution; in response they validated an eight‑item Ego‑Dissolution Inventory to improve measurement reliability. On therapeutic outcomes, small controlled and open‑label studies suggest potential benefits of psychedelics in anxiety, addiction and mood disorders. The extraction specifically cites a small open‑label pilot of psilocybin in treatment‑resistant depression that showed improvements in self‑reported depressive symptoms at three‑month follow‑up. In non‑clinical samples, psychedelic‑occasioned mystical or ego‑dissolution experiences have been associated with increased well‑being, rises in the personality trait openness and the perceived meaningfulness of the experience. The authors emphasise limitations across this evidence base: many clinical studies used strict exclusion criteria, had small sample sizes and relatively short follow‑up periods.

Carhart‑Harris frames the empirical pattern as evidence that the normal experience of a bounded self depends on the brain's modular resting‑state organisation and that transient disruptions of this modularity—brought about by psychedelics—can produce ego‑dissolution. Such findings, the authors contend, help connect phenomenological descriptions of the minimal self with measurable changes in network dynamics and oscillatory activity. They also note parallels between psychedelic‑induced network changes and neural correlates reported in non‑dual meditative states, suggesting common mechanisms for experiences of broadened or unified awareness. With respect to psychopathology, the review highlights that both schizophrenia and depression show abnormalities in self‑experience and in DMN activity; thereby, altered network organisation may be a shared substrate linking self‑disturbance and clinical symptoms. The authors regard psychedelics as useful investigative tools that can model aspects of abnormal self‑experience in a reversible and dose‑dependent manner. At the same time, they are cautious about therapeutic claims: while ego‑dissolution and mystical‑type experiences have been proposed as central to psychedelic therapy, the current clinical evidence is limited by small samples, exclusion criteria and short follow‑up. Key limitations acknowledged include the lack of validated measures in earlier work (which the Ego‑Dissolution Inventory aims to address), the preliminary nature of clinical findings, and the need for more rigorous, larger and longer‑term studies to test causal links between ego‑dissolution and lasting therapeutic change. The authors call for further research to clarify mechanisms and to determine whether inducing transient reductions in self‑boundaries can be harnessed safely and effectively in clinical settings.

The authors conclude that developing a neuroscience of self‑experience is important for basic neuroscience and for understanding psychiatric conditions characterised by self‑disturbance. Classic psychedelics reliably produce transient, dose‑dependent reductions in the normally well‑circumscribed sense of self (ego‑dissolution), and thus offer a valuable experimental tool to probe the neuronal correlates of normal and abnormal self‑experience. More speculatively, Carhart‑Harris and colleagues suggest that these ego‑dissolution experiences might have clinical utility when psychedelics are administered in controlled therapeutic environments, but they acknowledge that this possibility remains to be established. Note: the extracted Conclusion section contains a lengthy biographical passage about an individual (Michael/Laura/Laurence Dillon) that appears unrelated to the topic of psychedelics and self‑experience; this material seems to be an extraction artefact and is unlikely to reflect the paper's intended concluding content.